Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

Hanmi Pharmaceutical, a South Korean pharmaceutical giant, is making waves in the Latin American market with the launch of its innovative combination drug, 'Gugutams,' under the local brand name 'Aditams.' This move marks a significant step in the company's strategy to expand into emerging markets, particularly in Latin America. The launch, which took place in February 2025, follows an export agreement with Silanes, a leading Mexican pharmaceutical company. The collaboration is set to last for the next seven years, indicating a long-term commitment to the region.



Gugutams, developed by hanmi pharmaceutical, is a groundbreaking combination treatment for urological diseases. It combines 'tamsulosin,' a treatment for benign prostatic hyperplasia, and 'tadalafil,' a treatment for erectile dysfunction. This dual-action drug is the first of its kind in the domestic prescription drug market, utilizing Poly-Cap technology to combine multiple active ingredients in a single capsule. The drug is expected to offer a new treatment paradigm for patients suffering from both conditions, enhancing patient convenience and maximizing treatment efficacy.

The partnership with Silanes is a strategic move by Hanmi Pharmaceutical to navigate the complexities of the Mexican market. Silanes, founded in 1943, is a key player in the Latin American pharmaceutical market, known for its strengths in innovative healthcare solution research and development (R&D), production, and commercialization. The company has a robust distribution network and strategic collaborations with global partners, which will be instrumental in ensuring the successful launch and marketing of Gugutams in Mexico.

The launch of 'Aditams' in Mexico aligns with Hanmi Pharmaceutical's broader strategy for expanding into emerging markets. The company is focusing on regions like the Middle East and Latin America, using these as strategic entry points to broaden its collaborative product portfolio. This move is part of Hanmi's efforts to diversify its revenue streams and reduce its reliance on mature markets like North America and Japan. The company aims to use this partnership as a stepping stone to boost its global competitiveness.

However, entering the Mexican pharmaceutical market is not without its challenges. The regulatory environment is stringent, and the market is highly competitive. Hanmi Pharmaceutical has prepared to mitigate these risks through its partnership with Silanes. Silanes' extensive experience in the Mexican market and its robust distribution network will be crucial in navigating these challenges and ensuring the successful launch of 'Aditams.'

In summary, the launch of 'Aditams' in Mexico marks a significant step in Hanmi Pharmaceutical's strategy to expand into emerging markets. The partnership with Silanes provides the company with the regulatory expertise, market presence, and distribution network needed to successfully launch and market its innovative combination drug in Mexico. This move is expected to enhance patient convenience, maximize treatment efficacy, and strengthen Hanmi Pharmaceutical's position in the Latin American market.

Ask Aime: What impact does the launch of Hanmi Pharmaceutical's Gugutams in Mexico have on the Latin American market?